Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 113-119

  Wayua, Charity ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antagonist; Cancer imaging; Cholecystokinin 2 gastrin receptor; Nonpeptide; Radioimaging of tumors; Tumor targeted therapy

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; BENZODIAZEPINE DERIVATIVE; LIGAND; Z-360;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER SURGERY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TUMOR LEVEL; FEMALE; GAMMA SCINTIGRAPHY; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RADIODIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; ANIMAL; CANCER STAGING; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; BENZODIAZEPINONES; DIAGNOSTIC IMAGING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; LIGANDS; MICE; NEOPLASM STAGING; NEOPLASMS; RECEPTOR, CHOLECYSTOKININ B; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84920419750     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.144998     Document Type: Article

References (40)

1. Ivancevíc V, Wormann B, Nauck C, et al. Somatostatin receptor scintigraphy in the staging of lymphomas. Leuk Lymphoma. 1997; 26: 107-114.
2. 67Ga uptake with histology and transferrin receptor expression. J Nucl Med. 1999; 40: 40-45.
3. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002; 32: 97-109.
4. van Dam GM, Themelis G, Crane LMA, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: first inhuman results. Nat Med. 2011; 17: 1315-1319.
5. Zhang J, Razavian M, Tavakoli S, et al. Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 1849-1855.
6. Vaitilingam B, Chelvam V, Kularatne SA, Poh S, Ayala-Lopez W, Low PS. A folate receptor-a-specific ligand that targets cancer tissue and not sites of inflammation. J Nucl Med. 2012; 53: 1127-1134.
7. Kularatne SA, Zhou Z, Yang J, et al. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents. Mol Pharm. 2009; 6: 790-800.
8. Mantyh CRP, Pappas TN, Vigna SR. Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the canine upper gastrointestinal tract. Gastroenterology. 1994; 107: 1019-1030.
9. Little TJ, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes Rev. 2005; 6: 297-306.
10. Bowers ME, Choi DC, Ressler KJ. Neuropeptide regulation of fear and anxiety: implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behav. 2012; 107: 699-710.
11. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006; 86: 805-847.
12. Noble PJ, Wilde G, White MR. Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am J Physiol Gastrointest Liver Physiol. 2003; 284: G75-G84.
13. Oikonomou E, Buchfelder M, Adams EF. Cholecystokinin (CCK) and CCK receptor expression by human gliomas: evidence for an autocrine/paracrine stimulatory loop. Neuropeptides. 2008; 42: 255-265.
14. Wroblewski LE, Pritchard DM, Carter S, et al. Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J. 2002; 365: 873-879.
15. Watson SA, Grabowska AM, El-Zaatari M, et al. Gastrin: active participant or bystander in gastric carcinogenesis? Nat Rev Cancer. 2006; 6: 936-946.
16. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996; 67: 644-647.
17. Sethi T, Herget M, Wu SV, et al. CCK-A and CCK-B receptors are expressed in small cell lung cancer lines and mediate Ca21 mobilization and clonal growth. Cancer Res. 1993; 53: 5208-5213.
18. Reubi JCSJ, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997; 57: 1377-1386.
19. Hur K, Lee HJ, Park DJ, et al. Expression of gastrin and its receptor in human gastric cancer tissues. J Cancer Res Clin Oncol. 2006; 132: 85-91.
20. Körner M, Reubi JC, Miller LJ. CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. J Cell Mol Med. 2010; 14: 933-943.
21. Smith JP, Verderame MF, McLaughlin P, et al. Characterization of the CCKC (cancer) receptor in human pancreatic cancer. Int J Mol Med. 2002; 10: 689-694.
22. Olszewska-Pazdrak B, Townsend CM Jr, Hellmich MR. Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant. J Biol Chem. 2004; 279: 40400-40404.
23. Chao C, Goluszko E, Lee Y-T, et al. Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1a expression and tumor growth. Oncogene. 2007; 26: 1013-1019.
24. 111Inlabelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging. 2011; 38: 1410-1416.
25. 111In-labelled minigastrin. Eur J Nucl Med Mol Imaging. 2008; 35: 386-392.
26. 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging. 2011; 38: 1417-1425.
27. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998; 25: 424-430.
28. Behr TM, Béhé M, Angerstein C, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res. 1999; 5(10 suppl): 3124s-3138s.
29. Béhé M, Kluge G, Becker W, et al. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005; 46: 1012-1015.
30. Ocak M, Helbok A, Rangger C, et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides: a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging. 2011; 38: 1426-1435.
31. Lauffer DJ, Mullican MD. A practical synthesis of (S) 3-tert-butoxycarbonylamino- 2-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzodiazepine-1-acetic acid methyl ester as a conformationally restricted dipeptido-mimetic for caspase-1 (ICE) inhibitors. Bioorg Med Chem Lett. 2002; 12: 1225-1227.
32. Wayua C, Low PS. Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer. Mol Pharm. 2014; 11: 468-476.
33. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem. 2002; 13: 1200-1210.
34. Vlahov IR, You F, Wang Y, et al. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates. J Org Chem. 2010; 75: 3685-3691.
35. Kawasaki D, Emori Y, Eta R, et al. Effect of Z-360, a novel orally active CCK-2/ gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother Pharmacol. 2008; 61: 883-892.
36. Grabowska AM, Morris TM, McKenzie AJ, et al. Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models. Regul Pept. 2008; 146: 46-57.
37. Monstein HJ, Nylander AG, Salehi A, et al. Cholecystokinin-A and cholecystokinin- B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man: a polymerase chain reaction study. Scand J Gastroenterol. 1996; 31: 383-390.
38. Vegt E, Melis M, Eek A, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging. 2011; 38: 623-632.
39. Leelahavanichkul A, Bocharov AV, Kurlander R, et al. Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol. 2012; 188: 2749-2758.
40. Maack T, Johnson V, Kan T, et al. Renal filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int. 1979; 16: 251-270.